Home > Insider Trading > Filing (0000950170-25-080310)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1595097	Corbus Pharmaceuticals Holdings Inc.	CRBP	Pharmaceutical Preparations (2834)	464348039

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1947086	Anne Altmeyer	C/O Corbus Pharmaceuticals Holdings, Inc 500 River Ridge Drive Norwood MA 02062		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	Disposition	2025-05-30	1,392	$7.25	1,391	No	4	S	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2025-05-30	4,800	$0.00	6,191	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock options (right to buy)	Acquisiton	2025-05-30	16,000	$0.00	16,000	$7.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
16,000		2035-05-30	No	4	A	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.16 to $7.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
This amount includes 4,800 unvested RSUs that were granted on May 30, 2025.
The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.